France: State responsible for jogger's toxic algae death – DW – 06/24/2025
A court in Nantes found the French state bore partial responsibility for the 2016 death of Jean-Rene Auffray, who died of exposure to deadly toxins. The problem of toxic algae bloom stems from the region's farms.
A civil court in Nantes ruled Tuesday that the French government bore partial responsibility for the 2016 death of Jean-Rene Auffray, a 50-year-old jogger who suffered rapid pulmonary oedema, which sees the lungs fill with liquid, after he inhaled high concentrations of hydrogen sulfide on a beach in western Brittany.
In a statement, the court said that it "holds the state liable for negligence due to its failure to implement European and national regulations designed to protect waters from agricultural pollution," which is "the main cause of the proliferation of green algae in Brittany."
"For the first time, a French court has recognized the link between a person's death and the state's negligence in these green algae cases," said the family's lawyer, Francois Lafforgue.
Auffray's family sued the French government for his sudden death but lost its case in 2022 when the presiding judge ruled there had not been enough evidence to directly link it to algae rotting on the Gouessant estuary near the city of Saint-Brieuc.
On Tuesday, the Nantes court ruled that the French state was 60% responsible for Auffray's death but also noted that he had put himself at risk by jogging in the area.
Auffray's widow will receive €277,343 ($321,750), while each of his three children will receive €15,000, and his brother €9,000.
Brittany is a veritable agricultural powerhouse within France and is responsible for producing much of the country's dairy (one-third), poultry (one-half) and pork (one-third).
France has invested heavily in farming in the region for decades but that intensity and the excessive use of nitrate fertilizers combined with runoff from pig farms has led to massive algae bloom that chokes the coastal areas of the peninsula each year.
Deadly concentrations of sulfides released from the rotting stuff regularly close beaches in the region and cost French taxpayers millions as tons of algae are trucked off each summer.
France's top auditor reported in 2021 that an estimated 90% of Brittany's algae bloom could be traced back to farmers, who have significantly increased their use of nitrogen fertilizers since the 1960s.
To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
DW
3 hours ago
- DW
'Miracle' HIV drug lenacapavir approved amid US budget cuts – DW – 06/24/2025
The US has approved lenacapavir for HIV prevention. However, experts worry that cuts to the health budget will "squander" the drug's chance of reducing infections. The battle against HIV has been dealt repeated blows in 2025 with cuts to funding for major global aid programs by the United States. There have also been budget cuts closer to home. And experts have told DW the cuts risk undermining efforts to end the HIV epidemic in the US by 2030, even now, with the approval of lenacapavir — what UNAIDS officials have described as a "miracle" drug — in HIV prevention. Lencapavir provides six months of protection against HIV infection. The renowned journal named it 2024's scientific "breakthrough of the year." Some experts are asking whether the promise of the drug could be undone by the defunding of US public health agencies that are vital for getting lencapavir to those who need it most. "Are we going to squander this, probably the greatest opportunity in 44 years of HIV prevention both in the US and globally?" asked Mitchell Warren, executive director of the nonpartisan HIV organization AVAC, in an interview with DW. Winnie Byanyima, executive director of UNAIDS, the United Nations agency that addresses HIV and AIDS around the world, dubbed lenacapavir a "miracle product" in 2024. If it was hype, it was well-founded hype. In late-stage clinical trials, lenacapavir had a near-perfect record of suppressing HIV infection. Having already approved it as a treatment to reduce viral load in patients with the disease, the US Food and Drug Administration has now confirmed lenacapavir as a pre-exposure prophylaxis (PrEP) drug. PrEP drugs are taken before having unprotected sex or injecting drugs to protect against HIV. Unlike other PrEP drugs, which aim to disrupt the virus at one stage of its life cycle, lencapavir has been shown to attack HIV at several stages, increasing its effectiveness. About 400,000 US patients use some form of PrEP, usually a daily pill. But a twice-a-year injection with lenacapavir would provide people with the longest-lasting protection yet. To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video In his first term, US President Donald Trump started an "Ending the HIV Epidemic" (EHE) initiative, an effort to stop the transmission of the disease within the US by the end of this decade. But the current Trump administration's cost-cutting drive has downsized the federal health budget, affecting key public health agencies, such as the National Institutes of Health (NIH) and Centers for Disease Control and Prevention (CDC), and programs including Medicare and Medicaid. America's global aid initiatives, including USAID and PEPFAR (the President's Emergency Plan for AIDS Relief), have also been substantially wound back. "Whether it's the NIH research infrastructure [or] USAID for foreign assistance, these are big programs and none of them are HIV specific," Warren said. "But each one of them is diminished now in [its ability] to deliver the comprehensive and integrated programs that have been really at the forefront [of HIV response]." The result of this lost funding, Warren said, is that especially vulnerable groups, such as those from low-income backgrounds, gay and bisexual men and sex workers, may not benefit from the new PrEP drug, lenacapavir, which could provide them with unprecedented protection. Research has found that in US states which have expanded Medicaid coverage to offer health services to "all people with household incomes below a certain level," a growing number of people are using PrEP. Jeffrey Crowley, director of the Center for HIV and Infectious Disease Policy at the O'Neill Institute in Washington, said services like expanded Medicaid coverage have meant better access to HIV programs for those with the disease. "This is an incredible accomplishment, and it's helped drive a lot of the progress we've seen," Crowley told DW. He also said the cuts will mean people lose access to HIV services, which other programs can't cover. "I think the American people can be proud of how we responded to the HIV crisis domestically and globally, but this is all at risk. We've come so far, after so much death, why would we take a step backward?" To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video Every year, more than a million new HIV cases are reported globally and, until recently, US support through programs like USAID and PEPFAR was essential in helping regions most affected by the disease, especially countries in Africa. However, the Trump administration's aid withdrawal has already had an impact. Data from UNAIDS suggests there will be 2,300 more HIV cases per year because of the cuts to PEPFAR alone. Annual infections to date were already at about 3,500. "Less funding means we will get more and more off track," said Byanyima in mid-June. "We don't know what the total impact [of the US cuts] will be, but impact there will be. Already, you see in several countries a drop in the number of people going to clinics." The US government continues to support pregnant women and new mothers via PEPFAR, but the changes have stopped access to PrEP for gay and bisexual men, sex workers and drug users — groups that are disproportionately affected by HIV. Warren said it was akin to "throwing out a whole generation" of progress.
DW
5 hours ago
- DW
Need for vigilance amid new 'Nimbus' COVID variant – DW – 06/25/2025
A new Omicron subvariant has caused infections and deaths in South and Southeast Asia. Europe may see a spike after population immunity fell over the winter. What you need to know European health authorities are warning there may be an increase in COVID-19 infections in the coming months amid the spread of the new Omicron variant NB.1.8.1. or "Nimbus." "We have — what feels like — a fairly standard suite of recommendations that are being repeated," Ajibola Omokanye, an ECDC respiratory viruses expert, told DW. "But we remain watchful." The 2024-2025 winter in the Northern Hemisphere has given experts like Omokanye good reason to be watchful. Population immunity against SARS-CoV-2, the virus that causes COVID-19, is down in Europe, probably due to fewer COVID cases over the winter. As a result, Omokanye said there may be an increase in infections over the European summer. That may include severe cases that require treatment in hospital. To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video SARS-CoV-2 is becoming more endemic in communities but it is "still not a season pathogen, like influenza," said Omokanye. COVID still appears to move and mutate in unpredictable ways and that "stresses the need for continued vigilance and not being complacent about SARS-CoV-2,' said Omokanye. "Just in the same way that we're not complacent about influenza or RSV." Bangladesh has already seen deaths due to COVID in June. China and Singapore have also detected new cases of the respiratory disease. Deaths in places like Bangladesh may be partly due to people's poor access to healthcare. By comparison, Omokanye cited Canada, where Nimbus is dominant but without the same rates or severity of cases. But it's not only a case of access to healthcare. "There are multiple factors. First, it's the timing of [a] variant's emergence," Omokanye said. Another, he said, is that a there could be a greater possibility for waning immunity where there's been low circulation for a long period of time. With vaccination, there are also several important factors: Which vaccines are available in each country or region and "who they are given to and when," said Omokanye. "The question is: are the vaccines being taken up by that proportion of the population where you see the most severe disease?" Similarly with healthcare systems and access to supportive treatment, because localized differences may determine how seriously infections progress in a population. "They all contribute to the picture for severe disease," said Omokanye. To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video ECDC and the World Health Organization have classified Nimbus as a Variant under Monitoring (VOM) due to two specific spike mutations. The spikes are the "prongs" that enable the virus to latch onto and infect human cells. They have regularly mutated since SARS-CoV-2 first emerged. Spike protein mutations reduce the ability of human antibodies to neutralize an infection and others that enhance the virus' ability to evade human antibodies. VOM is the lowest category in a system where the more severe stages are Variant of Interest and Variant of Concern.
DW
7 hours ago
- DW
Thailand moves to make recreational cannabis illegal again – DW – 06/25/2025
Three years after decriminalizing cananbis, Thailand is on course to reclassify it as a narcotic, potentially collapsing a $1 billion industry and shutting down thousands of cannabis shops in popular tourist areas. Thailand is set to reclassify cannabis as a narcotic only three years after the country became one of Asia's first to decriminalize its recreational use. Coming in the wake of a government coalition split, the major policy reversal would renew controls on the recreational use of cannabis and shut down a booming $1 billion (€860 million) industry. Thailand removed cannabis from its narcotics list in 2022 but failed to implement a regulatory framework, allowing tens of thousands of cannabis shops to open, many in popular tourist areas. Government spokesman Jirayu Houngsub said the unregulated market has caused social issues, especially among young people. "The policy must return to its original goal of controlling cannabis for medical use only," he said. The decision also comes after the withdrawal of the Bhumjaithai Party — once the main advocate for legalization — from Prime Minister Paetongtarn Shinawatra's ruling coalition. The split followed criticism of Shinawatra's handling of a border dispute with Cambodia. Late Tuesday, the health ministry issued an order banning recreational cannabis sales and requiring a doctor's prescription for any legal purchase. The new regulations will take effect once published in the Royal Gazette, expected in the coming days. To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video "Cannabis will be classified as a narcotic in the future," quotes Health Minister Somsak Thepsuthin as saying. The Thai Chamber of Commerce had estimated the industry — covering both recreational and medicinal cannabis — could have been worth $1.2 billion by 2025.
